Intravenous Ketamine for Treatment-Resistant Depression

Inclusion Criteria:

• Ability to provide informed consent

• Meets diagnostic criteria for major depressive disorder without psychotic featuresper the SCID DSM-IV-TR

• PHQ-9 total score ≥ 15 at screening

• Treatment-resistant depression, as defined by failure of at least two previousantidepressant treatments within the current depressive episode. Failedantidepressant treatments can include pharmacotherapy for depression at an adequatedose for at least 8 weeks, trial of transcranial magnetic stimulation (TMS) or anacute series of at least 6 administrations of electroconvulsive therapy (ECT)

• Ability to pass a comprehension assessment test related to effects of ketamine andtrial objectives and criteria

Exclusion Criteria:

• Inability to speak English

• Inability to provide consent or have a legal guardian

• Patients with a BMI > 40 kg/m2.

• Personality disorder being the primary diagnosis

• Diagnosis of schizophrenia, schizoaffective disorder, bipolar disorder, or activepsychotic symptoms

• Active post-traumatic stress disorder symptoms based on clinical assessment

• Ongoing prescription of > 2 mg lorazepam equivalents (total) daily, or morningdosing of any benzodiazepine at the time of assessment

• Medications known to affect glutamate (i.e., Riluzole, Carbamazepine) or GABA (zaleplon, zolpidem, zopiclone, Valproate, Gabapentin, Pregabalin, tiagabine, andvigabatrin) are prohibited within two weeks prior to administration of study drugand at least 24 hours after last dose of study drug

• Monoamine Oxidase Inhibitors (MAOIs) are prohibited two weeks prior toadministration of study drug

• Opioid antagonists (naltrexone, naloxone, nalmefene, methylnaltrexone, buprenorphineand naloxone combination) are prohibited within two weeks prior to administration ofstudy drug and at least 24 hours after last dose of study drug

• CYP3A4 inducers carbamazepine and modafinil are prohibited within two weeks prior toadministration of study drug and at least 24 hours after last dose of study drug.

• Currently undergoing TMS, vagal nerve stimulation, or deep brain stimulation aseither an acute or maintenance treatment of depression

• ECT in the past 6 months

• Any active or unstable medical condition judged by the study psychiatrist asconferring too great a level of medical risk to allow inclusion in the study

• A history of bleeding in the brain

• Arteriovenous malformation or a history of aneurysm

• Use of methamphetamine, cocaine, or cannabis. Abuse of stimulant (s) within theprior 12 months

• Any current substance use disorder (excluding nicotine and caffeine). Note: Personswill be allowed to enroll in this study if their substance use is in complete (notpartial) and sustained (> 1 year) remission

• History of traumatic brain injury that resulted in loss of consciousness

• History of tonic-clonic (grand mal) seizures

• Developmental delay, intellectual disability, or intellectual disorder

• Clinical or self-reported diagnosis of delirium, encephalopathy, or related clinicaldiagnosis within the prior 12 months

• Minor or Major Neurocognitive disorder

• Received ketamine treatment for depression within the prior 2 months

• History of either poor antidepressive response to or poor tolerability of ketamine (any route of administration) when previously administered

• History of hypothyroidism unless taking a stable dose of thyroid medication andasymptomatic for 6 months

• Hepatic insufficiency (2.5 X ULN for AST or ALT) within 1 year of consent, pastliver transplant recipient, and/or clinical diagnosis of cirrhosis of the liver

• Gastroesophageal reflux disease that is poorly managed

• A diagnosis of Complex Regional Pain Syndrome (CRPS)

• Pregnancy, or nursing

• History of claustrophobia with active symptoms that would interfere with the MRI

• Any contraindication to MRI safety questionnaire